TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7900617
Drug: Atenolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (200 mg/day)
Study: 3310569
Drug: Acebutolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (400 mg/day)
Study: 6117063
Drug: Oxprenolol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (160 mg/day)
Study: 19395973
Drug: Tramadol alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol alone (1.5 mg kg(‐1))
Study: 19395973
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tramadol (1 mg kg(‐1)) and paracetamol 1 g
Study: 17484874
Drug: Telaprevir 450
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir 450 mg every 8 hours
Study: 24316262
Drug: Telaprevir 750
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir 750 mg every 8 hours
Study: 17484874
Drug: Telaprevir 1250
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir 1250 mg every 12 hours
Study: 11642016
Drug: Continuous administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration of Tazocin (12 g/1.5 g a day)
Study: 7802464
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days simultaneously continuous injection of 5-FU with Leucovorin (C)
Study: 20051692
Drug: 3 million
Normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 million IU of recombinant interleukin-2 (rIL-2) left in the cysts after transvaginal ultrasound-guided drainage (group II) twice
Study: 10225069
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of morphine with lidocaine (0.44‐0.98 mg.kg‐1.h‐1)
Study: 8519216
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of 0.5 mg captopril (n = 16)
Study: 3027839
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of itraconazole per day for five days
Study: 3027837
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of itraconazole per day for five days
Study: 22459724
Drug: Escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10 mg daily for four weeks
Study: 21738622
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for four weeks
Study: 12507707
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion (50-500 microg kg(‐1) x min(‐1))
Study: 12507707
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion (0.05-0.5 microg kg(‐1) x min(‐1))
Study: 6138072
Drug: Vesparax (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vesparax (150 mg secobarbital, 50 mg brallobarbital, 50 mg hydroxyzine)
Study: 31618540
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (pravastatin)
Study: 23438935
Drug: Acetazolamide 250
Normalized name: acetazolamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 250 mg bid
Study: 15277331
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 to 100 mg/d
Study: 8301727
Drug: Saphenous vein
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saphenous vein patch (VP) closure
Study: 8301727
Drug: Obligatory vein
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obligatory vein patch (OVP) closure
Study: 3291646
Drug: Propofol, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol, 2 mg/kg-propofol infusion, 1-20 mg/min-nitrous oxide, 60-70%
Study: 3291646
Drug: Thiopental, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental, 4 mg/kg-isoflurane, 0.2-3%-nitrous oxide, 60-70% (control)
Study: 25352617
Drug: Eight-week, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eight-week, twice weekly, 90-minute exercise and education programme
Study: 23415171
Drug: CRAS patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRAS patients with CHF (after 100% oxygen administration)
Study: 3516262
Drug: 5-FU i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU i.v. weekly for 12 months
Study: 29286595
Drug: Galantamine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (8 mg/d) plus standard methadone maintenance treatment (TAU)
Study: 29286595
Drug: Computerized CBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized CBT plus standard methadone treatment (TAU)
Study: 22930115
Drug: Prasugrel 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 60 mg loading dose / 10 mg maintenance dose
Study: 22930115
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose clopidogrel 150 mg maintenance dose
Study: 329712
Drug: Pentobarbital (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbital (50 or 150 mg) or sodium secobarbital (50 or 150 mg) or placebo
Study: 329712
Drug: Morphine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (5 or 10 mg) or meperidine (50 or 100 mg) or placebo
Study: 31260793
Drug: Obeticholic acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Obeticholic acid (OCA) 25 mg
Study: 23637733
Drug: 7.5 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 µg H1N1pnd09 antigen with MF59‐adjuvant (Pa7.5 µg)
Study: 18790032
Drug: Candid V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Candid V gel (marketed clotrimazole gel)
Study: 7978176
Drug: Neostigmine 0.036
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.036 mg/kg body weight
Study: 7978176
Drug: Neostigmine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine administration timing
Study: 3398555
Drug: Oral dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dipyridamole (19 patients)
Study: 3398555
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and intravenous dipyridamole
Study: 23593327
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 400 mg orally thrice daily for 8 weeks
Study: 26853137
Drug: Stop antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop antihypertensive drugs
Study: 8904857
Drug: Bronchodilator therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator therapy (albuterol or ipratropium bromide)
Study: 31144427
Drug: Vildagliptin in
Normalized name: Product containing vildagliptin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin in combination with metformin
Study: 29564872
Drug: 8% omega-ceramides,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% omega-ceramides, hydrophilic sugars, 5% niacinamide cream applied twice daily (group A)
Study: 24798767
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg zinc supplementation for 24 weeks
Study: 20362710
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of EPA + DHA and 2 g of ALA
Study: 8847861
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg diltiazem OD
Study: 8847861
Drug: 360 mg
Normalized name: aspirin 360 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg diltiazem OD
Study: 8847861
Drug: 420 mg
Normalized name: choline 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 420 mg diltiazem OD
Study: 27042750
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human GH (rhGH) treatment with 25(OH)D below the 50th percentile
Study: 22454414
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² IV over 1 hour for 21 days plus prednisone 5 mg orally twice per day (DP)
Study: 12490735
Drug: Fulvestrant 250
Normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant 250 mg monthly by intramuscular injection
Study: 31969301
Drug: Simvastatin 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 1% gel
Study: 22004512
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion at 2 kcal/min (G2)
Study: 22004512
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion at 4 kcal/min (G4)
Study: 22004512
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion at 1 kcal/min (G1)
Study: 9734735
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion
Study: 19223626
Drug: EDP-420 (100-1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP-420 (100-1200 mg)
Study: 19223626
Drug: EDP-420 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP-420 (400 mg)
Study: 17961376
Drug: Selective‐adrenoceptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective‐adrenoceptor antagonists (terazosin, doxazosin, tamsulosin, naftopidil)
Study: 17961376
Drug: 5 alpha‐reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 alpha‐reductase inhibitors (finasteride, epristeride)
Study: 12486870
Drug: Calcium (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1000 mg elemental calcium per day for 2 months)
Study: 9655592
Drug: Combination teaching
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination teaching approach
Study: 7864689
Drug: disease modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: disease modifying antirheumatic drug therapy
Study: 15309445
Drug: Plain release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain release vitamin C (2 x 250 mg daily) with vitamin E (2 x 91 mg)
Study: 15079004
Drug: Triflusal 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal 600 mg daily
Study: 20117379
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg daily
Study: 419761
Drug: Hexestrol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexestrol treatment for 12 months or longer
Study: 26088721
Drug: Fentanyl iontophoretic
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl iontophoretic transdermal system (ITS) 40 μg/dose
Study: 19912069
Drug: Oral PR
Normalized name: Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PR oxycodone/naloxone
Study: 19912069
Drug: Oral PR
Normalized name: Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PR oxycodone
Study: 15034826
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin (20 mg/kg per day; maximum dose, 1000 mg/day) for 5 days
Study: 15034826
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone (75 mg/day; maximum dose, 2.5 g/day) for 5 days
Study: 25799808
Drug: Amoxicillin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (40 mg/kg/day) for 7 days
Study: 19231545
Drug: Real interferential
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real interferential therapy (IFT) sessions, 12 sessions over a 4-week period.
Study: 15179026
Drug: Ayahuasca (0.85
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayahuasca (0.85 mg DMT/kg body weight)
Study: 31340842
Drug: 4CMenB booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB booster dose
Study: 30691980
Drug: 2 catch-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 catch-up doses of 4CMenB (vaccine-naïve)
Study: 30691980
Drug: 4CMenB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB vaccine (Primed_4y and Primed_7.5y)
Study: 30691980
Drug: 4CMenB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB vaccine (Naïve_4y and Naïve_7.5y)
Study: 21636012
Drug: Nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplementation of hop rho iso-alpha acids (200 mg), berberine sulfate trihydrate (100 mg), vitamin D₃ (500 IU), and vitamin K₁ (500 μg) twice daily
Study: 17651103
Drug: Low-dose dobutamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dobutamine infusion (10 microg/kg/min)
Study: 24843963
Drug: Acupuncture-moxibustion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture-moxibustion therapy
Study: 11475729
Drug: Qianliekang tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qianliekang tablets (Control)
Study: 8549036
Drug: Rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (600 mg once daily for 5 days)
Study: 3888857
Drug: Oxyfedrine (8-24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxyfedrine (8-24 mg three times a day)
Study: 3888857
Drug: Propranolol (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40-80 mg three times a day)
Study: 26062785
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg memantine
Study: 24940052
Drug: Calcium fructoborate
Normalized name: CALCIUM FRUCTOBORATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium fructoborate (CFB) 110 mg twice per day
Study: 18070439
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose midazolam sedation
Study: 15681985
Drug: Emotional and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emotional and educational intervention focusing on recurrence of breast cancer, 4 weeks duration, weekly meetings
Study: 10588463
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg of warfarin daily in combination with 75 mg of aspirin
Study: 8921777
Drug: Baseline HDL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline HDL cholesterol (1.39 mmol/L) and triglycerides (1.62 mmol/L for fasting participants)
Study: 8921777
Drug: Fasting participants
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting participants with triglycerides < 4.52 mmol/L
Study: 1495150
Drug: Silver sulfadiazine
Normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver sulfadiazine 1% cream
Study: 1495150
Drug: Biologically active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologically active tripeptide copper complex 0.4% cream
Study: 16763388
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone provocation test
Study: 16763388
Drug: D-xylose absorption
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-xylose absorption test and fecal fat measurement
Study: 11513909
Drug: Hydroxychloroquine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (200 or 400 mg depending on bodyweight)
Study: 8290452
Drug: HAD Hand
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAD Hand Wash (povidone-iodine alcoholic disinfectant solution)
Study: 8290452
Drug: Benzalkonium chloride
Normalized name: Benzalkonium Chloride
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzalkonium chloride alcoholic lotion
Study: 29624463
Drug: Adjuvant androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant androgen deprivation therapy (ADT)
Study: 29624463
Drug: Adjuvant androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant androgen deprivation therapy (ADT) plus mitoxantrone and prednisone (MP)
Study: 2107242
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered for 8 weeks
Study: 19432501
Drug: Olmesartan 40
Normalized name: HCTZ 25/OLMESARTAN 40MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 40 mg plus Amlodipine 5 mg or 10 mg
Study: 19432501
Drug: Olmesartan 40
Normalized name: HCTZ 25/OLMESARTAN 40MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 40 mg plus Amlodipine 10 mg
Study: 15784799
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (single dose of vitamin E)
Study: 12436823
Drug: Local delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local delivery of antimicrobial agents
Study: 3336109
Drug: Systemic antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antimicrobial agents
Study: 9745150
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (LRS) 1,500 ml at 25 ml/min
Study: 9745150
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch (HES) 500 ml at 25 ml/min
Study: 7821060
Drug: High-dose radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radiation therapy (5 fractions of 3.5 Gy each)
Study: 2568015
Drug: H2-receptor antagonists
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-receptor antagonists
Study: 25415737
Drug: Small doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small doxorubicin drug-eluting beads (100-300 µm)
Study: 25415737
Drug: Large doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large doxorubicin drug-eluting beads (300-500 and 500-700 µm)
Study: 20881754
Drug: Nizatidine controlled
Normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nizatidine controlled release (CR) 150 mg
Study: 20881754
Drug: Nizatidine controlled
Normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nizatidine controlled release (CR) 300 mg
Study: 15840681
Drug: CsA microemulsion,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA microemulsion, steroids, mycophenolate sodium and basiliximab
Study: 11832356
Drug: Acetaminophen (ACET;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (ACET; 4,000 mg/day)
Study: 7772487
Drug: Topical cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporin (CyA) 500 mg as a swish-and-spit medication for 5 min three times daily for 6 weeks
Study: 7772487
Drug: Corticosteroid oral
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid oral paste (triamcinolone acetonide) for 6 weeks
Study: 25125716
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of testosterone
Study: 18182868
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation program (2 sessions, 2 hours daily for 5 days)
Study: 9506749
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose flunisolide (H FN, 2000 microg/day)
Study: 7534320
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (Norditropin, 4 I.U. twice daily) for 6 weeks
Study: 8319375
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone
Study: 7036400
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg sublingually
Study: 30169980
Drug: Melatonin solution
Normalized name: melatonin Oral Solution
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin solution
Study: 10331397
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion after exercise
Study: 30987551
Drug: Alpha lipoic
Normalized name: Alpha Lipoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha lipoic acid (ALA) 600 mg daily for 8 weeks
Study: 25942341
Drug: Stem cells
Normalized name: Stem cells, apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stem cells in combination with bioresorbable PLA/PGA membrane
Study: 16449111
Drug: 4% intrauterine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% intrauterine lidocaine infusion
Study: 17167254
Drug: 20% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% sucrose solution exposure 8 times/day
Study: 17167254
Drug: 20% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% sucrose solution exposure 10 times/day
Study: 10075384
Drug: Isoflavonoid supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavonoid supplement (55 mg daily including 30 mg genistein, 16 mg biochanin A, 1 mg daidzein, 8 mg formononetin)
Study: 10075384
Drug: Isoflavonoid supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavonoid supplement
Study: 7719894
Drug: Turbuhaler inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turbuhaler inhalation of terbutaline (0.125, 0.25, 0.5, 1.0, 2.0 mg doses)
Study: 7719894
Drug: Pressurized metered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurized metered dose inhaler inhalation of terbutaline (0.125, 0.25, 0.5, 1.0, 2.0 mg doses)
Study: 7719894
Drug: Turbuhaler and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turbuhaler and Pressurized metered dose inhaler
Study: 1827311
Drug: Spiroplatin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiroplatin at 30 mg/m2 by 4 h infusion every 3 weeks (recommended dose for phase II studies)
Study: 1827311
Drug: Spiroplatin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiroplatin at 35 mg/m2 (MTD for poor-risk patients)